Skip to main content
. 2020 Sep 8;11:996. doi: 10.3389/fneur.2020.00996

Table 2.

Descriptions of treatments following daclizumab (GMSR).

Drug given after daclizumab treatment (GMSR) “Wash out period” in months mean (SD, median) DMT had already been given previously to daclizumab (%) DMT aborted within 6 months following daclizumab (%)
Teriflunomide 2.6 (5.1, 1.4) 5.0% 31.6%
Rituximab 3.0 (2.5, 3.4) 0.0% 40.0%
Ocrelizumab 4.0 (2.7, 3.8) 0.0% 2.9%
Natalizumab 1.2 (0.7, 1.1) 13.3% 0.0%
Glatiramer acetate 2.8 (3.1, 2.5) 11.1% 12.5%
Fingolimod 2.8 (2.9, 2.4) 12.5% 11.1%
Dimethyl fumarate 2.4 (1.0, 2.4) 10.0% 20.0%
Cladribine 3.9 (1.8, 3.0) 0% 11.8%